Tare Bio
Tare Bio is developing a personalized vaccine platform designed to treat cancer and infectious diseases by targeting each patient's unique disease-specific markers. The technology aims to generate precise T-cell responses that eliminate existing disease while establishing long-term immunological memory to prevent recurrence. The platform is intended to be adaptable across multiple cancer types and infectious agents.
- Drug Discovery & Therapeutics
- Biotechnology
- Healthcare Technology
Funding
Raised to date
$500KRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Founder details are not available yet.
Product
Problem
Traditional vaccines are limited in their ability to treat established diseases, particularly cancer, where tumors evolve to evade the immune system. Existing therapeutic options often lack the specificity needed to target a patient's unique disease profile, leading to suboptimal treatment outcomes and significant side effects. There is a critical need for a platform that can rapidly design and produce personalized immunotherapies for a wide range of oncological and infectious diseases.
Solution
Tare Bio is developing a proprietary platform for creating personalized vaccines tailored to an individual's specific cancer or infection. The technology focuses on identifying and targeting the unique neoantigens or pathogen-specific markers that distinguish a patient's disease from healthy tissue. By engineering vaccines that present these specific targets to the immune system, the platform aims to generate a potent and precise T-cell response. This approach is designed to not only eliminate existing disease but also to establish long-term immunological memory to prevent recurrence. The company's platform is intended to be adaptable, with the goal of creating a new class of therapeutic vaccines that can be applied across multiple cancer types and infectious agents.
Target Audience
Primary customers are oncology and infectious disease patients who have not responded to standard treatments, as well as the healthcare providers and clinical research organizations that manage their care.
Features
- Personalized neoantigen discovery and targeting to create patient-specific cancer vaccines.
- Platform designed for rapid vaccine design and production to address acute disease states.
- Technology applicable to both oncological and infectious disease targets.
- Aims to generate a robust T-cell mediated immune response for tumor destruction.
- Focus on creating durable immunological memory to prevent disease recurrence.